Accepted for/Published in: JMIR Formative Research
Date Submitted: Dec 16, 2024
Open Peer Review Period: Dec 16, 2024 - Feb 10, 2025
Date Accepted: Apr 7, 2025
(closed for review but you can still tweet)
Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States
ABSTRACT
Background:
Natural killer (NK)/T-cell lymphoma (NKTL) is a rare malignancy of mature NK/T-cells, with limited studies conducted in Western countries.
Objective:
The aim of this study is to present an overview of the incidence rate, demographic and clinical characteristics, treatment options, overall survival (OS), and factors influencing OS of NKTL in the United States.
Methods:
We utilized data from the Surveillance, Epidemiology, and End Results (SEER) 17 database to analyze NKTL cases recorded between 2000 and 2020. In a cohort of 1162 NKTL patients, we calculated the incidence rates and performed statistical analyses to evaluate OS, the effect of radiotherapy and chemotherapy on survival, and lymphoma-specific survival.
Results:
The mean annual incidence rate of NKTL in the United States was 0.067 per 100,000, which has remained stable in recent years. The median survival time for NKTL patients was 21 months, with a 5-year OS rate of 39.5%. Patients with the nasal type or with the use of combined radiotherapy and chemotherapy generally experience better survival.
Conclusions:
The incidence of NKTL has remained stable in recent years. Patients with the nasal type of NKTL generally experience better survival outcomes. The use of combined radiotherapy and chemotherapy appears to enhance survival.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.